Rolling submission has been initiated for a Biologics License Application, submitting data to the FDA for the potential approval of ciltacabtagene autoleucel for the treatment of adult patients with relapsed and/or refractory multiple myeloma.
In an interview with Targeted Oncology, Yi Lin, MD, PhD discussed the updated findings from the CRB-401 study of idecabtagene vicleucel as treatment of patients with relapsed/refractory multiple myeloma.
In an interview with Targeted Oncology, Mehmet Samur, PhD, discussed the investigation of high-dose melphalan following autologous stem cell transplant in patients with multiple myeloma and shared insights into how the ongoing questions can be explored in the future.
In an interview with Targeted Oncology, Jesus G. Berdeja, MD, discussed a subanalysis of the KarMMA study and updated results from CARTITUDE-1, which provide insights on the use CAR T-cell therapy in heavily pretreated patients with multiple myeloma, including the elderly and frail.
The combination of selinexor plus pomalidomide and low-dose dexamethasone led to favorable responses in a cohort of patients with heavily pretreated multiple myeloma, warranting further investigation of the regimen in a phase 3 trial.
A 20-mg 3-times-weekly or twice-weekly dosing schedule of panobinostat combined with subcutaneous bortezomib plus dexamethasone induced durable responses as treatment of patients with relapsed or refractory multiple myeloma and demonstrated an acceptable safety profile in the phase 2 PANORAMA 3 study.
Ixazomib in combination with lenalidomide plus dexamethasone achieved a clinically meaningful improvement of 13.5 months in the median progression-free survival as treatment of elderly patients with transplant-ineligible newly diagnosed multiple myeloma.
The combination of daratumumab with lenalidomide, bortezomib, and dexamethasone followed by maintenance therapy with daratumumab and lenalidomide improved response rates and depth of response rates with statistically significance as treatment of patients with transplant-eligible newly diagnosed multiple myeloma.